eFFECTOR Therapeutics, Inc.
EFTR
$0.0002
$0.000.00%
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 5.31M | 6.07M | 5.36M | 4.88M | 6.61M |
| Gross Profit | -5.31M | -6.07M | -5.36M | -4.88M | -6.61M |
| SG&A Expenses | 3.09M | 2.52M | 2.50M | 2.97M | 2.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.40M | 8.60M | 7.86M | 7.86M | 9.54M |
| Operating Income | -8.40M | -8.60M | -7.86M | -7.86M | -9.54M |
| Income Before Tax | -8.83M | -9.13M | -8.30M | -8.36M | -10.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.83M | -9.13M | -8.30M | -8.36M | -10.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.83M | -9.13M | -8.30M | -8.36M | -10.01M |
| EBIT | -8.40M | -8.60M | -7.86M | -7.86M | -9.54M |
| EBITDA | -8.37M | -8.57M | -7.83M | -7.83M | -9.51M |
| EPS Basic | -2.16 | -3.42 | -3.36 | -4.37 | -5.96 |
| Normalized Basic EPS | -1.35 | -2.14 | -2.10 | -2.73 | -3.73 |
| EPS Diluted | -2.16 | -3.42 | -3.36 | -4.37 | -5.96 |
| Normalized Diluted EPS | -1.35 | -2.14 | -2.10 | -2.73 | -3.73 |
| Average Basic Shares Outstanding | 4.08M | 2.67M | 2.47M | 1.91M | 1.68M |
| Average Diluted Shares Outstanding | 4.08M | 2.67M | 2.47M | 1.91M | 1.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |